Munshi Renuka, Panchal Falguni, Kumbhar Dipti
Department of Clinical Pharmacology, TN Medical College & BYL Nair Charitable Hospital, Mumbai Central, Mumbai, Maharashtra, India.
Department of Clinical Pharmacology, TN Medical College & BYL Nair Charitable Hospital, Mumbai Central, Mumbai, Maharashtra, India.
J Ayurveda Integr Med. 2025 May 29;16(3):101129. doi: 10.1016/j.jaim.2025.101129.
Ayurveda recommends an integrative approach of shodhana & shamana therapy for Obesity management.
This study evaluated the safety and efficacy of Navak Guggul and Lekhan Basti, individually and in combination, with respect to anthropometric, biochemical levels and transcriptional profiling of selected candidate genes in obese participants.
Single-centre, open-labelled, randomized, comparative, pilot study was conducted following Institutional Ethics Committee approval. 64 obese participants of either gender, aged between 25 and 60 years with BMI 28-32.9 kg/m and WHR (Men>0.90 and Women>0.85) were randomly allocated to four groups, each with 16 participants, to receive either Navak Guggul or Lekhan Basti, individually or in combination or no treatment in addition to diet and lifestyle modification. Anthropometric measurements, ayurvedic symptoms severity score, impact of weight on quality of life (IWQOL), biochemical tests and genetic expressions of select genes (UCP2, AD1POR1, FTO, GHRL, Leptin and PPARγ) were assessed at baseline (V1), immediately after therapy (V4) and 2 months post-therapy (V6).
50 participants completed the study. Participants from all groups showed significant reduction in BMI (except Group IV) with significant improvement in the ayurvedic symptoms score. Improvement in the IWQOL score was seen at V4 in all groups with maximal reduction in serum lipids in Groups I and III. Transcriptional profiling revealed increased expression of UCP2, ADIPOR1 and PPARγ genes at V4 and decreased expression of FTO, Ghrelin and Leptin genes compared to V1.
Lekhan Basti and combination therapy were beneficial in reducing anthropometric and lipid parameters. Several genes were differentially expressed immediately post-treatment suggesting their role as candidate genes in obesity management.
阿育吠陀医学推荐采用净化疗法和舒缓疗法相结合的方法来管理肥胖问题。
本研究评估了纳瓦克古古勒(Navak Guggul)和勒汗灌肠剂(Lekhan Basti)单独使用及联合使用时,对肥胖参与者的人体测量学指标、生化水平以及所选候选基因转录谱的安全性和有效性。
在获得机构伦理委员会批准后,开展了一项单中心、开放标签、随机、对照的试点研究。64名年龄在25至60岁之间、BMI为28 - 32.9 kg/m²且腰臀比(男性>0.90,女性>0.85)的肥胖参与者被随机分为四组,每组16人,分别接受纳瓦克古古勒或勒汗灌肠剂单独治疗、联合治疗或除饮食和生活方式改变外不接受任何治疗。在基线期(V1)、治疗结束后即刻(V4)和治疗后2个月(V6)评估人体测量学指标、阿育吠陀症状严重程度评分、体重对生活质量的影响(IWQOL)、生化检测以及所选基因(UCP2、AD1POR1、FTO、GHRL、瘦素和PPARγ)的基因表达。
50名参与者完成了研究。所有组的参与者BMI均显著降低(第四组除外),阿育吠陀症状评分显著改善。所有组在V4时IWQOL评分均有改善,第一组和第三组血清脂质降低最多。转录谱分析显示,与V1相比,V4时UCP2、ADIPORr1和PPARγ基因表达增加,FTO、胃泌素和瘦素基因表达降低。
勒汗灌肠剂及联合疗法有助于降低人体测量学指标和脂质参数。治疗后即刻有多个基因出现差异表达,表明它们在肥胖管理中作为候选基因发挥作用。